| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.046 | 0.4 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.2 | 0.4 |